2019-08-29 08:00
Significant events during the first quarter Significant events after the end of the period CEO’s comments Commercialization of DiviTum® for breast cancer During the first quarter of the new financial year, we achieved several important milestones in...
2019-08-28 07:55
Biovica has completed the supplement II process which includes written feedback and physical meetings with the FDA in order to define the process for clinical validation for 510(k) submission for DiviTum®. Biovica also announces that an agreement with...
2019-07-25 12:16
On the 22nd of July, Biovica had fruitful meeting with the FDA regarding Supplement II that discusses the approach for clinical validation of DiviTum. Next step is to document the conclusions from the meeting, which the FDA will review and signoff. This...
2019-06-28 08:00
Biovica’s annual report for the fiscal year 2018/2019 is published on our website http://www.biovica.com/investor-relations/financials/
2019-06-14 08:00
SEK thousands Q4 18/19 Q4 17/18 May-April 18/19 May-April 17/18
Net sales 1,715 1,433 ...
2019-05-22 09:45
Biovica has a comprehensive study program with DiviTum® to demonstrate the clinical value for cancer patients. Biovica has published a summary brochure in order to share knowledge about results achieved so far with DiviTum® to researchers, oncologists...
2019-05-08 11:09
Uppsala, Sweden, May 8, 2019: Biovica will participate in the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago May 31-June 4, 2019
2019-05-06 08:00
The strong results from the previously presented EFECT study have now been published in the scientific, and highly renowned, European Journal of Cancer (impact factor 7.191 which equals to top 3% of scientific journal ranking).
2019-05-02 13:30
The extra general meeting ("EGM") of Biovica International AB (publ) ("Biovica" or the "Company") was held today on 2 May 2019 and the following resolutions were passed by the meeting.
Resolution regarding approval of the board of directors' resolution...
2019-04-10 14:00
Uppsala, Sweden, April 10, 2019: Biovica has agreed on a collaboration with IBL-America for sales of DiviTum® for the research market in the US. The partnership will further increase the commercial activities for this customer segment on the single largest...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects